owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 11, 2016.

A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414:

1. First Busey Corporation, Champaign, Illinois; to merge with Pulaski Financial Corp., Saint Louis, Missouri, and thereby indirectly acquire Pulaski Bank, National Association, Creve Coeur, Missouri.

B. Federal Reserve Bank of Dallas (Robert L. Triplett III, Senior Vice President) 2200 North Pearl Street, Dallas, Texas 75201–2272:

1. First Commercial Financial Corp., Seguin Texas; to acquire by merger 100 percent of Jourdanton Bancshares, Inc., and indirectly, Jourdanton State Bank, both of Jourdanton, Texas.

Board of Governors of the Federal Reserve System, January 12, 2016.

Michael J. Lewandowski,

Associate Secretary of the Board. [FR Doc. 2016–00752 Filed 1–14–16; 8:45 am] BILLING CODE 6210–01–P

GENERAL SERVICES ADMINISTRATION

[Notice-2015-PM-04; Docket No. 2015-0002; Sequence No. 32]

Notice of Availability of the Final Supplemental Draft Environmental Impact Statement for the Federal Bureau of Investigation Central Records Complex in Winchester County, Virginia

AGENCY: General Services Administration (GSA). **ACTION:** Notice of availability.

SUMMARY: Pursuant to the National Environmental Policy Act (NEPA) of 1969, as implemented by the Council on Environmental Quality regulations, the GSA has prepared and filed with the **Environmental Protection Agency** (EPA), a Supplement to the Final Environmental Impact Statement (SEIS), from May 2007, analyzing the environmental impacts of site acquisition and development of the Federal Bureau of Investigation (FBI), Central Records Complex (CRC), in Frederick County, Virginia. DATES: Effective Date: The Final SEIS is now available for review. The GSA Record of Decision will be released no sooner than 30 days after EPA publishes its Notice of Availability of the Final SEIS in the Federal Register.

ADDRESSES: The Final SEIS may be viewed online at *http://www.fbicrcseis.com.* Paper copies may be viewed at the repositories listed under

SUPPLEMENTARY INFORMATION.

FOR FURTHER INFORMATION CONTACT: Ms. Courtenay Hoernemann, Project Environmental Planner, 100 S Independence Mall West, Philadelphia PA 19106; or email

frederick.va.siteacquisition@gsa.gov.

SUPPLEMENTARY INFORMATION: The proposed FBI facility would consolidate the FBI's records currently housed within the Washington DC area, in addition to field offices and information technology centers nationwide. The project requirements are for an overall square footage of 256,425 gross square feet, and will include the records storage building, support area, visitor's screening facility, service center, and guard booth. Parking is proposed at 427 spaces.

A Notice of Intent to prepare a Supplemental Draft EIS was published in the Federal Register at 80 FR 8311 on February 17, 2015. A public scoping comment period was held for 30 days following publication of the Notice of Intent. GSA published the Notice of Availability of the Supplemental Draft EIS on August 20, 2015 at 80 FR 50631, which began a 45 day public comment period ending on October 5, 2015. A public meeting was held on September 10, 2015 from 6:00 p.m. to 8:00 p.m., Eastern Standard Time (EST), at the War Memorial Building Social Hall at Jim Barnett Park, War Memorial Drive, Winchester, VA.

The Supplemental Draft EIS incorporated by reference and built upon the analyses presented in the 2007 Final EIS, and documented the section 106 process under the National Historic Preservation Act (NHPA) of 1966, as amended (36 CFR part 800). The Supplemental Draft EIS addressed changes to the proposed action relevant to environmental concerns and assessed any new circumstances or information relevant to potential environmental impacts. The alternatives fully evaluated in the Supplemental Draft EIS include the No Action Alternative, the Arcadia Route 50 property, and Whitehall Commerce Center.

The Final Supplemental EIS identifies XXX as the preferred alternative. The proposed action at XXX will result in impacts to water resources, traffic and transportation, biological resources, and geology/topography/soils. Changes between the Final and Draft Supplemental EIS include conclusion on consultation under section 106 of the NHPA, conclusion of consultation under section 7 of the Endangered Species Act with the U.S. Fish & Wildlife Service, and agreement with Virginia Department of Transportation on the Revised Traffic Impact Analysis and site access. The Final Supplemental EIS addresses and responds to agency and public comments on the Supplemental Draft EIS.

The Final Supplemental EIS has been distributed to various federal, state, and local agencies. The Final Supplemental EIS is available for review on the project Web site *http://www.fbicrc-seis.com*. A printed copy of the document is available for viewing at the following libraries:

• Handley Library, 100 West Piccadilly Street, P.O. Box 58, Winchester, VA 22604

• Bowman Library, 871 Tasker Road, P.O. Box 1300, Stephens City, VA 22655

• Smith Library, Shenandoah University, 718 Wade Miller Drive, Winchester, VA 22601

Dated: January 6, 2016.

John Hofmann,

Division Director, Facilities Management & Services Programs Division, General Services Administration, Mid-Atlantic Region.

[FR Doc. 2016–00330 Filed 1–14–16; 8:45 am]

BILLING CODE 6820-89-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Community Living

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Semi-Annual and Final Reporting Requirements for the Older Americans Act Title IV Discretionary Grants Program

AGENCY: Administration for Community Living, HHS.

ACTION: Notice.

SUMMARY: The Administration for Community Living (ACL) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments on the collection of information by February 16, 2016.

ADDRESSES: Submit written comments on the collection of information by email to *OIRA_submission@ omb.eop.gov* Attn: OMB Desk Officer for ACL, or by fax 202–395–6974, Office of Information and Regulatory Affairs, OMB.

FOR FURTHER INFORMATION CONTACT: Lori Stalbaum at (202) 357–3452, or

lori.stalbaum@acl.hhs.gov. SUPPLEMENTARY INFORMATION: In

compliance with 44 U.S.C. 3507, ACL has submitted the following proposed collection of information to OMB for review and clearance.

Describe Collection of Information

ACL is requesting to continue an existing approved collection of information for semi-annual and final reports pursuant to the requirements of its discretionary grant programs. ACL estimates the burden of this collection of information as follows: Frequency: Semi-annually with the Final report taking the place of the semi-annual report at the end of the final year of the grant. Respondents: States, public agencies, private nonprofit agencies, institutions of higher education, and organizations including tribal organizations. Estimated Number of Responses: 600. Total Estimated Burden Hours: 12,000.

Dated: January 12, 2016.

Kathy Greenlee,

Administrator and Assistant Secretary for Aging.

[FR Doc. 2016–00762 Filed 1–14–16; 8:45 am] BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-N-0001]

Navigating the Center for Drug Evaluation and Research: What You Should Know for Effective Engagement; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

SUMMARY: The Food and Drug Administrations (FDA) Center for Drug Evaluation and Research (CDER), is sponsoring a public workshop entitled "Navigating CDER: What You Should Know for Effective Engagement." The purpose of this public workshop is to help the public and patient advocacy groups gain a better understanding of how to effectively engage CDER. **DATES:** The public workshop will be held on March 31, 2016, from 8:30 a.m. to 5 p.m.

ADDRESSES: The public workshop will be held at FDA's White Oak campus, 10903 New Hampshire Ave., Building 31 (The Great Room A, B, and C), Silver Spring, MD 20993. Entrance for the public workshop participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to *http:// www.fda.gov/AboutFDA/Workingat FDA/BuildingsandFacilities/White OakCampusInformation/ ucm241740.htm.*

FOR FURTHER INFORMATION CONTACT:

Shawn Brooks, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 240–402–6509, email: *NAV-CDER@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: FDA is announcing a public workshop entitled "Navigating CDER: What You Should Know for Effective Engagement." This public workshop is intended to enhance the public and advocacy groups' ability to effectively engage FDA's CDER. The presentations are intended to provide information on how best to interact with CDER. There will be an opportunity for questions and answers following each presentation.

Registration: There is no registration fee to attend the public workshop. Early registration is recommended because seating is limited, and registration will be on a first-come, first-served basis. There will be no onsite registration. Persons interested in attending this workshop must register online at *http:// www.fda.gov/Drugs/NewsEvents/ ucm472604.htm* before March 24, 2016. For those without Internet access, please contact Shawn Brooks (see **FOR FURTHER INFORMATION CONTACT**) to register.

If you need special accommodations due to a disability, please contact Shawn Brooks (see FOR FURTHER INFORMATION CONTACT) at least 7 days in advance.

Transcripts: A transcript of the workshop will be available for review at

the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, and on the Internet at *http://www.regulations.gov* approximately 30 days after the workshop. Transcripts will also be available in either hard copy or on CD– ROM, after submission of a Freedom of Information request. The Freedom of Information office address is available on the Agency's Web site at *http:// www.fda.gov.*

Dated: January 8, 2016.

Leslie Kux,

Associate Commissioner for Policy. [FR Doc. 2016–00694 Filed 1–14–16; 8:45 am] BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-0001]

Advisory Committee: Vaccines and Related Biological Products Advisory Committee, Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; renewal of advisory committee.

SUMMARY: The Food and Drug Administration (FDA) is announcing the renewal of the Vaccines and Related **Biological Products Advisory** Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Vaccines and Related Biological Products Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until December 31, 2017. DATES: Authority for the Vaccines and **Related Biological Products Advisory** Committee will expire on December 31, 2017, unless the Commissioner formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT:

Sujata Vijh, Division of Scientific Advisors and Consultants, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6128, Silver Spring, MD 20993–0002, 240–402–7107, *Sujata.vijh@fda.hhs.gov.* **SUPPLEMENTARY INFORMATION:** Pursuant to 41 CFR 102–3.65 and approval by the Department of Health and Human Services pursuant to 45 CFR part 11 and by the General Services Administration, FDA is announcing the renewal of the